Critical Comparison: Invivo Therapeutics (NVIV) vs. Its Rivals

Invivo Therapeutics (NASDAQ: NVIV) is one of 80 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Invivo Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, earnings, profitability, dividends, risk and valuation.

Institutional and Insider Ownership

12.8% of Invivo Therapeutics shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 3.9% of Invivo Therapeutics shares are held by company insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Invivo Therapeutics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Invivo Therapeutics N/A -$23.43 million -0.84
Invivo Therapeutics Competitors $2.14 billion $234.27 million -88.24

Invivo Therapeutics’ rivals have higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Invivo Therapeutics has a beta of 3.21, suggesting that its share price is 221% more volatile than the S&P 500. Comparatively, Invivo Therapeutics’ rivals have a beta of 1.54, suggesting that their average share price is 54% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Invivo Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivo Therapeutics 0 1 0 0 2.00
Invivo Therapeutics Competitors 292 1959 3472 110 2.58

Invivo Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 741.28%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 3.94%. Given Invivo Therapeutics’ higher probable upside, analysts clearly believe Invivo Therapeutics is more favorable than its rivals.


This table compares Invivo Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivo Therapeutics N/A -134.23% -109.16%
Invivo Therapeutics Competitors -316.70% -24.05% -10.25%


Invivo Therapeutics rivals beat Invivo Therapeutics on 9 of the 13 factors compared.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply